|
- 2019
Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinomaDOI: 10.1038/s41698-019-0091-4 Keywords: Targeted therapies, Biliary tract cancer, Cancer genetics, Tumour heterogeneity, Tumour biomarkers Abstract:
|